Top 5 stories on HIV and women from CROI 2024
Top 5 HIV PrEP stories from CROI 2024
Should event-driven PrEP be an option for women?
Ultra-long-acting cabotegravir could be taken three times a year for HIV PrEP and treatment
Huge increase in PrEP uptake when services offer choice, flexibility and injectable PrEP, African study shows
Far fewer HIV infections in Australian PrEP users – consistent use is key
Six-country African PrEP study achieves high levels of persistence and good adherence in young women
HIV diagnoses continue to fall in US states with high PrEP coverage, while others are left behind
People need pathways from PEP to PrEP – and back again
